Status:
COMPLETED
PET Imaging of DHA Metabolism
Lead Sponsor:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Brief Summary
This study will examine the use of positron emission tomography (PET) for measuring docosahexaenoic acid (DHA) absorption from the blood into the brain. DHA is a type of fatty acid found in fish and o...
Detailed Description
Docosahexaenoic acid (DHA, 22:6 n-3) is an essential omega-3 fatty acid that is selectively concentrated in the brain. Epidemiologic studies suggest that DHA deficiency is related to affective disorde...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Age 18-65 years.
- EXCLUSION CRITERIA:
- Any Axis I diagnosis, current or past.
- History of any intravenous drug use, or a DSM IV diagnosis of drug use or alcohol abuse or dependence.
- Recent use (within the past two weeks) of alcohol, or any period of extensive use, defined as an average of one standard drink per day over a twelve-month period.
- Abnormal laboratory or diagnostic tests that might disturb the dependent measures of the study.
- Inability to give a clinical history or informed consent.
- Inability to follow dietary guidelines.
- Serious medical problems requiring ongoing treatment (i.e., diabetes or hypertension).
- Positive test for hepatitis C or human immunodeficiency virus (HIV).
- Metallic foreign bodies lodged in the head or neck that would be affected by the MRI scanner magnet.
- Head trauma resulting in a period of unconsciousness lasting longer than one hour.
- History of central nervous system infection.
- History of fetal alcohol syndrome or other neurodevelopment disorder.
- History of seizures, other than in childhood and related to fever.
- Nursing women, women with a positive pregnancy test or women of childbearing age who are not willing to use some form of birth control during the study.
- Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits of exposure.
- Current use of cigarettes, cigars, or other form of tobacco, defined as ten cigarettes, two pipes or two cigars over the preceding month.
- Current drug or medication use, or the use of any medication (i.e., Tylenol) for three days prior to PET.
- Positive urine drug screen.
- Psychotropic medication use (including benzodiazepines and illicit drugs) during the two weeks prior to the PET scan. The use of medication with a very long half life (i.e., Prozac) during the six weeks prior to the PET scan.
Exclusion
Key Trial Info
Start Date :
December 12 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 13 2010
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00074503
Start Date
December 12 2003
End Date
July 13 2010
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892